Skip to main content

BIOFIRE® Respiratory 2.1 (RP2.1) & Respiratory 2.1 plus (RP2.1plus)  Panels 

1 Test. Up to 23 Targets. ~45 Minutes. 

The BIOFIRE RP2.1 and RP2.1plus Panels use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients. 

  

Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.

BIOFIRE® RP2.1plus Panel is not available for sale in the USA.

Overview

Simple, Comprehensive Respiratory Testing 

The BIOFIRE Respiratory 2.1 and 2.1plus Panels are frontline tests to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others. Fast and comprehensive, the panels offer a run time of about 45 minutes, enabling high efficiency and throughput on the BIOFIRE®FILMARRAY® TORCH System. Rapid respiratory PCR test results may enable better-informed diagnosis and treatment of patients. Quick turnaround time on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, cohorting, and additional diagnostic testing.

  • Simple: 2 minutes hands-on time
  • Fast: Turnaround time of about 45 minutes
  • Comprehensive:
    • RP2.1: 22 targets (18 Viruses, 4 bacteria)
    • RP2.1plus: 23 targets (19 Viruses, 4 bacteria)
  • Accurate: Overall 97.1% sensitivity and 99.3% specificity (prospective specimens)* SARS-CoV-2 98.4% PPA and 98.9% NPA**
  • Increased diagnostic yield and co-detection1

*Based on the prospective portion of the clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 Panel

**Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 Panel in comparison to 3 EUA tests, Data on file, BioFire Diagnostics.

  

Improve Clinical Outcomes

Because clinical symptoms for different respiratory illnesses are usually very similar, in vitro diagnostic molecular methods are often necessary to determine the causative agents. Early, rapid, and specific detection using nested multiplex PCR is essential to provide patient-tailored therapy for better outcomes. An accurate diagnosis may also help to control outbreaks, reduce potential antimicrobial resistance (AMR), and facilitate a more rapid patient recovery.

Studies show that the BIOFIRE Respiratory 2.1 and 2.1plus Panels can deliver excellent clinical and economic outcomes:

  • Dramatically reduce time to diagnosis.2-4,6
  • Improve patient management.2-6 
  • Reduce total cost of care and resource utilization.6
  • Prevent secondary spread of infection.5,6
  • Prevent exposure to unnecessary antibiotics.3-6
  • Detect more positives and co-infections than non-panel assays.1
  • Provide more timely and effective treatment.3-6
  • Result in shorter hospital stays.4,6
  • Reduce unnecessary or ancillary testing.4,5

References

1. Kitano, Taito et al. J Infect Chemother. 2020;26(1):82-85. doi:10.1016/j.jiac.2019.07.014

2. Pettit N, et al. J. Med Microbiol., March 2015 64:312-313.

3. Gelfer G, et al. Diag Micro Infect Dis. 2015;83:400-406.

4. Rappo U, et al. J. Clin. Microbiol. JCM.00549-16.

5. Subramony A, et al. J Pediatr. 2016; doi:10.1016/jpeds. 2016.02.050.

6. Rogers BB, et al. Arch Pathol Lab Med. 2015;139:636-641.

 

Panels Menu

The BIOFIRE® Respiratory 2.1 (RP2.1) Panel Menu

Viruses

  • Adenovirus
  • Coronavirus 229E
  • Coronavirus HKU1
  • Coronavirus NL63
  • Coronavirus OC43
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

 

  • Human metapneumovirus
  • Human rhinovirus/enterovirus
  • Influenza A virus
  • Influenza A virus A/H1
  • Influenza A virus A/H3
  • Influenza A virus A/H1-2009

 

  • Influenza B virus
  • Parainfluenza virus 1
  • Parainfluenza virus 2
  • Parainfluenza virus 3
  • Parainfluenza virus 4
  • Respiratory syncytial virus

Bacteria

  • Bordetella parapertussis
  • Bordetella pertussis
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

FDA Cleared


The BIOFIRE® Respiratory 2.1plus (RP2.1plus) Panel Menu

Viruses

  • Adenovirus Coronavirus 229E
  • Coronavirus HKU1
  • Coronavirus NL63
  • Coronavirus OC43
  • Middle East respiratory syndrome coronavirus (MERS-CoV)
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

 

  • Human metapneumovirus
  • Human rhinovirus/enterovirus
  • Influenza A virus
  • Influenza A virus A/H1
  • Influenza A virus A/H3
  • Influenza A virus A/H1-2009

 

  • Influenza B virus
  • Parainfluenza virus 1
  • Parainfluenza virus 2
  • Parainfluenza virus 3
  • Parainfluenza virus 4
  • Respiratory syncytial virus

Bacteria

  • Bordetella parapertussis
  • Bordetella pertussis
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

Services & Support

Customer Support: bioMérieux offers the best possible support with dedicated BIOFIRE® technical experts.

Application Specialists: bioMérieux has dedicated support teams available to help set up equipment and troubleshoot any issues.

For assistance: please contact our customer technical support team at biofiresupport@biomerieux.com